Medullary thyroid carcinoma (MTC) is frequently associated with multiple endocrine neoplasia type 2 (MEN2) disorders and can be either spontaneous or inherited. Compared to other thyroid tumors, medullary thyroid carcinoma is more aggressive and has the potential to spread to distant organs and lymph nodes. Genetic tests, imaging, and increased levels of calcitonin and carcinoembryonic antigen (CEA) are all part of the diagnosis. The foundation of treatment is a complete thyroidectomy. In more severe situations, tailored therapy may be used. Moreover, its rising prevalence is anticipated to positively impact the pipeline landscape for medullary thyroid cancer drugs.
Major companies involved in the medullary thyroid cancer treatment market include Sanofi, Eli Lilly and Company and Epizyme, Inc., among others.
Leading drugs currently under the pipeline include Vandetanib and LOXO-260, among others.
The increasing cases of medullary thyroid cancer and the rising technological advancements are poised to positively influence the medullary thyroid cancer pipeline landscape.
The Medullary Thyroid Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into medullary thyroid cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for medullary thyroid cancer. The medullary thyroid cancer report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The medullary thyroid cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with medullary thyroid cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to medullary thyroid cancer.
Medullary thyroid cancer results in an overabundance of calcitonin production. Mutations in the RET proto-oncogene, especially in hereditary cases (MEN2A, MEN2B), are the cause of it. Unchecked cell proliferation, angiogenesis, and metastasis are all encouraged by RET activation. Somatic RET mutations are frequently found in sporadic MTC cases. Fibrosis, amyloid buildup, and lymphatic or hematogenous dissemination are the results of tumor growth. Biomarkers include elevated CEA and calcitonin. Targeted therapies like RET inhibitors are required for advanced patients who show resistance to standard therapy.
RET inhibitors are the most widely used treatment for medullary thyroid carcinoma. These medications stop the growth and spread of tumors by targeting abnormal RET signalling, a major cause of medullary thyroid cancer. Both hereditary and sporadic medullary thyroid cancer patients benefit from them, particularly those including RET mutations. Because of their targeted mechanism, oral bioavailability, and superior results compared to traditional medicines, small molecule inhibitors are the preferred treatment for advanced or metastatic medullary thyroid cancer. Further, the rising focus on the development of medullary thyroid cancer emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
About 2% to 5% of all thyroid tumors are medullary thyroid carcinomas (MTCs), an uncommon kind of thyroid cancer. Every year, about 1,000 people in the United States receive a diagnosis of medullary thyroid cancer. Unlike the more prevalent papillary and follicular thyroid tumors, which start from follicular cells, medullary thyroid cancer arises from parafollicular or C cells, which generate calcitonin. Over the past few decades, there has been a small increase in the prevalence of medullary thyroid cancer. The majority of the cases are sporadic, with around 20% being hereditary. About 83% of people with medullary thyroid cancer survive for five years.
This section of the report covers the analysis of medullary thyroid cancer drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of medullary thyroid cancer drugs undergoing clinical development.
The drug molecule categories covered under medullary thyroid cancer pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The medullary thyroid cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for medullary thyroid cancer.
The EMR report for the medullary thyroid cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed medullary thyroid cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in medullary thyroid cancer clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Sanofi, vandetanib is a medullary thyroid cancer drug candidate under investigation for its efficacy and safety in the affected patients. The study is under Phase III clinical development.
Eli Lilly and Company is conducting a study aimed at examining the efficacy of the investigational drug LOXO-260 for the treatment of medullary thyroid cancer. The study is under Phase I clinical development.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Medullary Thyroid Cancer Drug Report provides a strategic overview of the latest and future landscape of treatments for medullary thyroid cancer. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within medullary thyroid cancer pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share